Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-06-23
1998-06-16
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
560 59, 558426, 549 13, 549 74, 549426, 549491, 548131, 548146, 548202, 548215, 548236, 548247, 5482674, 548254, 5483001, 5483361, 5483751, 548561, 546152, 546230, 546330, 544106, 544242, 544358, 5142395, 514255, 514269, 514277, 514311, 514315, 514364, 514365, 514374, 514378, 514381, 514383, 514396, 514406, 514427, 514432, 514438, 514451, 514461, 514530, A61K 31215, A61K 31275, C07C 69708, C07C25537
Patent
active
057671516
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/US95/16841 filed Dec. 21, 1995.
FIELD OF INVENTION
The present invention relates to novel 3,3-(disubstituted)cyclohexan-1-ylidine acetate dimers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).
BACKGROUND OF THE INVENTION
Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.
Identification of novel therapeutic agents for asthma is made difficult by the fact that multiple mediators are responsible for the development of the disease. Thus, it seems unlikely that eliminating the effects of a single mediator will have a substantial effect on all three components of chronic asthma. An alternative to the "mediator approach" is to regulate the activity of the cells responsible for the pathophysiology of the disease.
One such way is by elevating levels of cAMP (adenosine cyclic 3', 5'-monophosphate). Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, International Congress Excerpta Medica, 17-29, 1973!. When the appropriate agonist binds to specific cell surface receptors, adenylate cyclase is activated, which converts Mg.sup.+2 -ATP to cAMP at an accelerated rate.
Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma. As such, an elevation of cAMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of monocyte and macrophage activation. Hence, compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells. The principal cellular mechanism for the inactivation of cAMP is hydrolysis of the 3'-phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs).
It has now been shown that a distinct cyclic nucleotide phosphodiesterase (PDE) isozyme, PDE IV, is responsible for cAMP breakdown in airway smooth Potential Targets for Novel Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd., 1989!. Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils. Moreover, the beneficial effects of PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo. Thus PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E.sub.2 and prostacyclin (activators of adenylate cyclase) are elevated. Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
The compounds of this invention also inhibit the production of Tumor Necrosis Factor (TNF), a serum glycoprotein. Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia se
REFERENCES:
patent: 5449686 (1995-09-01), Christensen et al.
J.P. Mazaleyrat, "Synthesese de cetones encombrees via Reduction de nitriles tertiares en Presence de Metaux alcalins", (1978), Can J. Chem., vol. 56, NO. 21, pp. 2731-2736.
Christensen, IV Siegfried B.
Karpinski Joseph M.
Dees Jos,e G.
Kanagy James M.
Lentz Edward T.
SmithKline Beecham Corporation
Stockton Laura L.
LandOfFree
3,3-(disubstituted) cyclohexan-1-ylidine acetate dimers and rela does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,3-(disubstituted) cyclohexan-1-ylidine acetate dimers and rela, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,3-(disubstituted) cyclohexan-1-ylidine acetate dimers and rela will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726474